Related Experiment Video
Updated: May 23, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
HMGB1 is a therapeutic target for leukemia
American Journal of Blood Research
|March 21, 2012
Summary
High mobility group box 1 (HMGB1) is implicated in leukemia development and treatment resistance. Targeting HMGB1 shows promise for overcoming chemotherapy resistance in leukemia patients.
Area of Science:
- Molecular biology
- Immunology
- Oncology
Background:
- High mobility group box 1 (HMGB1) is a nuclear protein acting as a Damage-Associated Molecular Pattern (DAMP) upon cellular stress.
- HMGB1 is increasingly recognized for its role in leukemia pathogenesis and resistance to chemotherapy.
Purpose of the Study:
- To investigate the role of HMGB1 in leukemia, focusing on its impact on apoptosis, autophagy, and chemotherapy resistance.
- To evaluate HMGB1 as a potential therapeutic target for leukemia treatment.
Main Methods:
- Analysis of serum HMGB1 levels in childhood acute lymphocytic leukemia patients compared to controls and remission groups.
- Investigation of HMGB1's regulatory effects on apoptosis (Bcl-2 expression, caspase-3 activity) and autophagy (interaction with Beclin 1) in leukemia cells.
- Assessment of experimental strategies targeting HMGB1 to overcome chemotherapy resistance.
Main Results:
- Serum HMGB1 levels were elevated in childhood acute lymphocytic leukemia patients.
- HMGB1 negatively regulates apoptosis and positively regulates autophagy and cell survival in leukemia cells.
- Targeting HMGB1 effectively reversed and prevented chemotherapy resistance in experimental models.
Conclusions:
- HMGB1 plays a significant role in promoting leukemia cell survival and chemoresistance.
- HMGB1 represents a promising novel therapeutic target for leukemia treatment.
- Further research into HMGB1-targeted therapies could improve outcomes for leukemia patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...